Auris Medical (NASDAQ: EARS) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Auris Medical to similar businesses based on the strength of its analyst recommendations, dividends, risk, profitability, valuation, institutional ownership and earnings.
Institutional & Insider Ownership
25.2% of Auris Medical shares are held by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.4% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Auris Medical and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Auris Medical||N/A||-$31.13 million||-0.74|
|Auris Medical Competitors||$290.27 million||$35.99 million||60.32|
Auris Medical’s rivals have higher revenue and earnings than Auris Medical. Auris Medical is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Auris Medical has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Auris Medical’s rivals have a beta of 5.81, suggesting that their average stock price is 481% more volatile than the S&P 500.
This table compares Auris Medical and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Auris Medical Competitors||-5,441.68%||-162.70%||-35.92%|
This is a breakdown of current ratings for Auris Medical and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Auris Medical Competitors||1134||3426||11925||240||2.67|
Auris Medical presently has a consensus target price of $4.50, indicating a potential upside of 837.89%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.60%. Given Auris Medical’s stronger consensus rating and higher probable upside, equities analysts plainly believe Auris Medical is more favorable than its rivals.
Auris Medical rivals beat Auris Medical on 8 of the 12 factors compared.
Auris Medical Company Profile
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration. Its second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL). It intends to conduct over two pivotal Phase III trials in the treatment of idiopathic sudden SNHL (ISSNHL), titled Acute Inner Ear Hearing Loss (HEALOS) and Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT). AM-111 received orphan drug designation for the treatment of ASNHL from the United States Food and Drug Administration, and the European Union agency. It intends to conduct a Phase II trial in the treatment of surgery-induced hearing loss (REACH).
Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.